We are live on
!
Find out more
ACP
Acuta Capital Partners Portfolio holdings
AUM
$143M
1-Year Est. Return
773.18%
This Fund
S&P 500
This Quarter
Est. Return
+18.29%
1 Year Est. Return
+773.18%
3 Year Est. Return
+7,269.42%
5 Year Est. Return
+14,284.66%
10 Year Est. Return
+1,769,765.59%
AUM
$250M
AUM Growth
-$27.1M
(-9.8%)
Cap. Flow
-$55.7M
Cap. Flow
% of AUM
-22.26%
Top 10 Holdings %
Top 10 Hldgs %
58.37%
Holding
52
New
6
Increased
8
Reduced
20
Closed
14
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Aligos Therapeutics
ALGS
|
+$5.46M |
| 2 |
CYT
Cyteir Therapeutics, Inc. Common Stock
CYT
|
+$5.2M |
| 3 |
SEEL
Seelos Therapeutics, Inc. Common Stock
SEEL
|
+$4.88M |
| 4 |
GH Research
GHRS
|
+$3.06M |
| 5 |
RAIN
Rain Oncology Inc. Common Stock
RAIN
|
+$2.84M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ETNB
89bio
ETNB
|
+$9.32M |
| 2 |
Curis
CRIS
|
+$8.69M |
| 3 |
TRIL
Trillium Therapeutics Inc.
TRIL
|
+$7.11M |
| 4 |
MRSN
Mersana Therapeutics
MRSN
|
+$5.79M |
| 5 |
Altimmune
ALT
|
+$5.75M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 87.44% |
| 2 | Miscellaneous | 6.78% |
| 3 | Financials | 5.78% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
VistaGen Therapeutics
VTGN
$10.4M
| $36.9M | 14.76% |
390,934
-18,925
| -5% | -$1.4M |
|
2
Celldex Therapeutics
CLDX
$3.06B
| $33M | 13.19% |
987,406
-30,118
| -3% | -$827K |
|
|
3
PUT
Celldex Therapeutics
CLDX
$3.06B
| $16.7M | 6.68% |
+500,000
| New | +$13.7M |
|
|
APLS
4
DELISTED
Apellis Pharmaceuticals
APLS
| $10.1M | 4.05% |
160,500
+47,339
| +42% | +$2.44M |
|
5
Arrowhead Research
ARWR
$9.57B
| $8.95M | 3.57% |
108,000
| – | – |
|
|
BLSA
6
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
| $8.88M | 3.55% |
843,122
| – | – |
|
7
Verastem
VSTM
$684M
| $8.21M | 3.28% |
168,203
-22,913
| -12% | -$955K |
|
|
ISEE
8
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $7.89M | 3.15% |
1,250,000
-329,093
| -21% | -$2.12M |
|
9
Xenon Pharmaceuticals
XENE
$5.55B
| $7.77M | 3.11% |
417,409
+4,909
| +1% | +$90.5K |
|
|
SEEL
10
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
| $7.55M | 3.02% |
745
+297
| +66% | +$4.88M |
|
11
Kura Oncology
KURA
$1.04B
| $7.37M | 2.94% |
353,398
-183,422
| -34% | -$4.55M |
|
|
EPIX
12
DELISTED
ESSA Pharma
EPIX
| $6.65M | 2.66% |
232,896
-54,104
| -19% | -$1.57M |
|
|
CLSD
13
DELISTED
Clearside Biomedical
CLSD
| $6.41M | 2.56% |
87,751
-19,849
| -18% | -$922K |
|
14
Fulcrum Therapeutics
FULC
$288M
| $6.33M | 2.53% |
604,074
-18,426
| -3% | -$186K |
|
|
VINC
15
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
| $6.21M | 2.48% |
23,920
+4,220
| +21% | +$1.29M |
|
|
CYT
16
DELISTED
Cyteir Therapeutics, Inc. Common Stock
CYT
| $5.94M | 2.38% |
+277,777
| New | +$5.2M |
|
|
JYAC
17
DELISTED
Jiya Acquisition Corp. Class A Common Stock
JYAC
| $5.59M | 2.23% |
562,500
| – | – |
|
|
LONA
18
LeonaBio Inc
LONA
$65.5M
| $4.37M | 1.75% |
42,706
+2,706
| +7% | +$472K |
|
|
19
Aligos Therapeutics
ALGS
$32.3M
| $4.37M | 1.75% |
+8,570
| New | +$5.46M |
|
20
Cartesian Therapeutics
RNAC
$238M
| $4.28M | 1.71% |
34,156
+6,723
| +25% | +$801K |
|
|
CMRX
21
DELISTED
Chimerix, Inc.
CMRX
| $4.07M | 1.63% |
509,164
-198,666
| -28% | -$1.65M |
|
22
Orchestra BioMed
OBIO
$347M
| $4M | 1.6% |
392,500
| – | – |
|
23
Iovance Biotherapeutics
IOVA
$4.54B
| $3.89M | 1.55% |
149,495
+51,921
| +53% | +$1.35M |
|
|
AVDL
24
DELISTED
Avadel Pharmaceuticals
AVDL
| $3.78M | 1.51% |
561,011
-533,989
| -49% | -$4.24M |
|
25
Syndax Pharmaceuticals
SNDX
$1.58B
| $3.54M | 1.41% |
206,126
-49,054
| -19% | -$898K |
|
Similar funds
FPC
WWM
AVA
BOM
PWM
FF
JPT
BJF
Acuta Capital Partners's Q2 2021 Portfolio in Review
As of Q2 2021, Acuta Capital Partners held 52 positions worth $250M, down 9.8% from $277M the previous quarter. Its ten largest holdings account for 58% of the portfolio.
Acuta Capital Partners withdrew a net $55.7M in Q2 2021, closing 14 positions and reducing 20 holdings. Its most notable exit was 89bio, an estimated $9.32M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 87% of assets, down from 94% a quarter earlier, followed by Miscellaneous and Financials.
Against the trend, Acuta Capital Partners opened a new position in Aligos Therapeutics worth $4.37M.
- Acuta Capital Partners's largest Q2 2021 buy was Aligos Therapeutics: 8,570 shares worth $4.37M.
- Acuta Capital Partners added most to Seelos Therapeutics, Inc. Common Stock in Q2 2021, an estimated $4.88M increase.
- Acuta Capital Partners's biggest Q2 2021 reduction was Sage Therapeutics, cutting an estimated $4.78M.
- Acuta Capital Partners fully exited 89bio in Q2 2021, selling an estimated $9.32M.
- Acuta Capital Partners's ten largest holdings make up 58% of its $250M portfolio in Q2 2021.
- Acuta Capital Partners opened 6 new positions and closed 14 in Q2 2021.
- Acuta Capital Partners's portfolio value fell 9.8% quarter-over-quarter to $250M.
Based on Acuta Capital Partners's 13F filing for Q2 2021, filed 16 Aug 2021.